Cover Image
市場調查報告書

E3泛素蛋白連接酶Mdm2:開發中產品分析

E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.) - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 369092
出版日期 內容資訊 英文 73 Pages
訂單完成後即時交付
價格
Back to Top
E3泛素蛋白連接酶Mdm2:開發中產品分析 E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.) - Pipeline Review, H2 2016
出版日期: 2016年08月10日 內容資訊: 英文 73 Pages
簡介

本報告提供以E3泛素蛋白連接酶Mdm2為標的治療藥之開發平台現狀及最新更新的各開發階段比較分析,提供您附最新的新聞和發表之企業和研究機關開發中之治療藥,治療藥評估,後期階段及中止的計劃等相關資訊。

簡介

  • 調查範圍

E3泛素蛋白連接酶Mdm2 概要

治療藥的開發

  • 開發中的產品:各開發階段
  • 開發中的產品:各治療領域
  • 開發中的產品:不同症狀

開發中產品概況

  • 後期階段的產品
  • 初期階段的產品

企業開發中的產品

大學/機關開發中的產品

治療藥的評估

  • 單劑/並用治療藥的情況
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

治療藥的開發企業

  • Aileron Therapeutics, Inc.
  • Amgen Inc.
  • Ascentage Pharma Group Corporation, Ltd.
  • 第一三共
  • F. Hoffmann-La Roche Ltd.
  • Merck & Co., Inc.
  • Novartis AG

藥物簡介

暫停中的計劃

開發中止的產品

主要消息及新聞稿

附錄

圖表

目錄
Product Code: GMDHC0462TDB

Summary

Global Markets Direct's, 'E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.) - Pipeline Review, H2 2016', provides in depth analysis on E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.) targeted pipeline therapeutics.

The report provides comprehensive information on the E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape for E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.)
  • The report reviews E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.) targeted therapeutics and enlists all their major and minor projects
  • The report assesses E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.) Overview
  • Therapeutics Development
    • E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.) - Products under Development by Stage of Development
    • E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.) - Products under Development by Therapy Area
    • E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.) - Products under Development by Indication
  • E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.) - Pipeline Products Glance
    • Late Stage Products
    • Early Stage Products
  • E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.) - Products under Development by Companies
  • E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.) - Products under Development by Universities/Institutes
  • E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.) - Therapeutics Assessment
    • Assessment by Monotherapy/Combination Products
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.) - Companies Involved in Therapeutics Development
    • Aileron Therapeutics, Inc.
    • Amgen Inc.
    • Ascentage Pharma Group Corporation, Ltd.
    • Daiichi Sankyo Company, Limited
    • F. Hoffmann-La Roche Ltd.
    • Merck & Co., Inc.
    • Novartis AG
  • E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.) - Drug Profiles
    • ALRN-6924 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AM-7209 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AMG-232 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • APG-115 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ATSP-7041 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CGM-097 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • DS-3032 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • DS-5272 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • HDM-201 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • idasanutlin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ISA-27 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MI-888 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MK-8242 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MMRi-64 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • nutlin-3 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • R-xxx - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RG-7775 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RO-8994 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule 1 to Inhibit MDM2 for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule 2 to Inhibit MDM2 for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule 3 to Inhibit MDM2 for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit MDM2 and MDM4 for Acute Lymphoblastic Leukemia - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit MDM2 for Breast Cancer - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit p53-hdm2 for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit p53-MDM2 Interaction for Cancer - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Target Hdm2 for Proliferative Vitreoretinopathy - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Vaccine to Target CD105, Yb-1, SOX2, CDH3 and MDM2 for Breast Cancer - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.) - Dormant Projects
  • E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.) - Discontinued Products
  • E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.) - Featured News & Press Releases
    • Feb 12, 2015: Aileron Therapeutics Initiates Phase 1 Cancer Study of ALRN-6924 in Advanced Hematologic and Solid Malignancies with Wild Type p53
    • Dec 05, 2014: Roche to present clinical data on RG-7388 at ASH
    • Aug 15, 2013: Aileron Therapeutics Publishes Data Demonstrating ATSP-7041 as First-in-class p53 Pathway Re-activator for the Treatment of Solid and Hematologic Cancers
    • Nov 07, 2012: Aileron Therapeutics Presents New Data On Stapled Peptide Oncology Program At EORTC-NCI-AACR Symposium On Molecular Targets And Cancer Therapeutics
    • Oct 31, 2012: Aileron Therapeutics To Present Data On Stapled Peptides At Upcoming Scientific Conferences And Industry Events
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for, H2 2016
  • Number of Products under Development by Therapy Area, H2 2016
  • Number of Products under Development by Indication, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016 (Contd..1)
  • Products under Development by Companies, H2 2016 (Contd..2)
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Products under Investigation by Universities/Institutes, H2 2016
  • Assessment by Monotherapy/Combination Products, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Pipeline by Aileron Therapeutics, Inc., H2 2016
  • Pipeline by Amgen Inc., H2 2016
  • Pipeline by Ascentage Pharma Group Corporation, Ltd., H2 2016
  • Pipeline by Daiichi Sankyo Company, Limited, H2 2016
  • Pipeline by F. Hoffmann-La Roche Ltd., H2 2016
  • Pipeline by Merck & Co., Inc., H2 2016
  • Pipeline by Novartis AG, H2 2016
  • Dormant Projects, H2 2016
  • Dormant Projects (Contd..1), H2 2016
  • Dormant Projects (Contd..2), H2 2016
  • Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for, H2 2016
  • Number of Products under Development by Therapy Area, H2 2016
  • Number of Products under Development by Top 10 Indication, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy/Combination Products, H2 2016
  • Number of Products by Stage and Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
Back to Top